Skip to main content

6-K

Indivior Pharmaceuticals, Inc. (INDV)

6-K 2025-02-04 For: 2025-02-04
View Original
Added on July 07, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

________________________

Washington, D.C. 20549

_____________________

FORM 6-K

_____________________

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of February 2025

Commission File Number: 001-37835

________________________________________

Indivior PLC

________________________________________

10710 Midlothian Turnpike, Suite 125

North Chesterfield, Virginia 23235

(Address of principal executive office)

_______________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit<br>No. Description<br>of Exhibit
99.1 Announcement sent<br>to the London Stock Exchange on February 04, 2025, titled<br>“Transaction in Own Shares”.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Indivior PLC
Date: February 04,<br>2025 /s/<br>Kathryn Hudson
Name:<br>Kathryn Hudson
Title:<br>Company Secretary

a7330v-1

Exhibit 99.1

INDIVIOR PLC

SHARE REPURCHASE PROGRAM

WEEKLY REPORT

February 4, 2025

INDIVIOR PLC ("Indivior") announces that it purchased for cancellation a total of 204,247 of its ordinary shares of $0.50 each through Morgan Stanley & Co. International Plc in the period from January 27, 2025, up to and including January 31, 2025, in connection with its $100m Share Repurchase Program. Aggregated information on the purchase of these shares can be found in the table below.

Following the purchase and cancellation of the above shares (including those purchased but not yet settled), Indivior has 124,137,286 ordinary shares of $0.50 each with voting rights in issue. There are no shares held in treasury.

The above figure (124,137,286) may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Indivior under the FCA's Disclosure Guidance and Transparency Rules.

All repurchases by Indivior are "On Exchange" transactions (as such term is defined in the rules of the London Stock Exchange) and "on market" for the purposes of the Companies Act 2006.

Aggregated information

Trading<br>Date Trading<br>Venue Aggregated<br>daily volume (number of shares) Daily<br>weighted average purchase price of the shares (p)
27/01/2025 LSE 15,225 964.57
27/01/2025 BATE 5,912 963.95
27/01/2025 CHIX 18,321 965.68
27/01/2025 AQUIS 2,442 967.02
28/01/2025 LSE 20,092 982.38
28/01/2025 BATE 4,586 984.79
28/01/2025 CHIX 14,490 982.55
28/01/2025 AQUIS 2,330 985.06
29/01/2025 LSE 20,652 987.47
29/01/2025 BATE 3,602 990.21
29/01/2025 CHIX 15,514 988.73
29/01/2025 AQUIS 1,068 993.23
30/01/2025 LSE 14,877 982.26
30/01/2025 BATE 7,449 983.03
30/01/2025 CHIX 16,455 982.00
30/01/2025 AQUIS 1,734 980.91
31/01/2025 LSE 9,956 979.80
31/01/2025 BATE 6,684 979.75
31/01/2025 CHIX 19,365 976.14
31/01/2025 AQUIS 3,493 990.02

Transaction details

In accordance with Article 5(1)(b) of the assimilated Market Abuse Regulation (EU) No 596/2014, as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018 and Commission Delegated Regulation (EU) 2016/1052, a full breakdown of the individual purchases of ordinary shares made by Morgan Stanley & Co. International Plc on behalf of Indivior during the above period as part of the Share Repurchase Program can be found at www.indivior.com/en/investors/shareholder-information/share-repurchase-program.

Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.

Contact:

Jason Thompson

Vice President, Investor Relations

1-804-402-7123